Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Unknown 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Other solid neoplasm 5

Conditions

Carcinoma, Hepatocellular 23Carcinoma, Non-Small-Cell Lung 12Colorectal Neoplasms 8Biliary Tract Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Mesothelioma, Malignant 5Melanoma 5Liver Neoplasms 5Cholangiocarcinoma 5Urinary Bladder Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Diabetes Mellitus, Insulin-Dependent, 12 4Neoplasm Metastasis 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Ovarian Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Mesothelioma 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Adenocarcinoma Of Esophagus 2Vascular Neoplasms 1Uveal Melanoma 1

Interventions

Cisplatin 28Pemetrexed 22Gemcitabine 10Nivolumab 9Carboplatin 9pembrolizumab 8tremelimumab 5durvalumab 5atezolizumab 5Radiotherapy 5Doxorubicin 4Chemotherapy, Adjuvant 4Vinorelbine 3Ipilimumab 3Bortezomib 3Bevacizumab 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2sodium thiosulfate 2sargramostim 2niraparib 2nintedanib 2liposomal doxorubicin 2lenvatinib 2defactinib 2cemiplimab 2cediranib 2amatuximab 2Trabectedin 2Neoadjuvant Therapy 2Mitomycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma, Malignant × tremelimumab × Clear all
NCT01843374 2026-03-05

Tremelimumab

MedImmune LLC

Phase 2 Active not recruiting
571 enrolled 19 charts
Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT05380713 2025-12-29

......SMARTEST Trial......

University Health Network, Toronto

Phase 2 Completed
30 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02588131 2015-10-27

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Italian Network for Tumor Biotherapy Foundation

Phase 2 Unknown
40 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01655888 2012-08-02

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

Azienda Ospedaliera Universitaria Senese

Phase 2 Unknown
29 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01649024 2012-07-25

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Azienda Ospedaliera Universitaria Senese

Phase 2 Unknown
29 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡